1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag

Saniona publishes its interim report for the second quarter of 2023

MAR
Three Months Ended June 30, 2023 (2022)Six Months Ended June 30, 2023 (2022)
Revenue was SEK 3.9 M (3.0 M)Revenue was SEK 6.0 M (9.6 M)
Operating profit/loss was SEK -21.8 M (-91.8 M)Operating profit/loss was SEK -42.9 M (-225.0 M)
Net profit/loss was SEK -21.2 M (-88.6 M)Net profit/loss was SEK -43.0 M (-221.9 M)
Basic earnings/loss per share was SEK -0.34 (-1.42)Basic earnings/loss per share was SEK -0.69 (-3.56)
Diluted earnings/loss per share were SEK -0.34 (-1.42)Diluted earnings/loss per share were SEK -0.69 (-3.56)

Business highlights in Q2 2023

  • Pierandrea Muglia was at the Annual General Meeting May 25, 2023, elected as a new ordinary board member.

Significant events after the reporting period

  • On July 17, Saniona announced a new collaboration agreement with AstronauTx in Alzheimer’s disease.
  • In August, Saniona announced a change to the terms of the loan agreement with Formue Nord. The parties agreed to reduce the loan value, through a repayment of 3 MSEK by Saniona and a conversion of 10 MSEK into shares at 8.50 SEK per share, and changed the maturity date to January 31, 2025.

Comments from the CEO
“We have established an additional partnership with the research collaboration with AstronauTx in Alzheimer’s disease. Our objectives are unchanged, and we are working diligently with potential partners with the aim of reaching an additional partnership this year.”

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona’s most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona’s partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-31 08:00 CEST.

Attachments
20230831 Saniona Q2 2023 (UK)

Datum 2023-08-31, kl 08:00
Källa MFN
Bifogade filer
20230831 Saniona Q2 2023 (UK)
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!